Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $554.32M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 2.66M
Average 3.76M
SANA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Sana Biotechnology, Inc.NASDAQ: SANA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $35.48M fell 29.9% year over year, behind the +10.6% change in trailing-twelve-month operating expenses. Sequentially, it fell 42.0% from the prior quarter. Over 3 fiscal years it compounded at -13.2% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.9% toward the trailing-twelve-month pace of +10.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 178.21M USD
- Year-over-year change
- -34.7%
- 4-year CAGR
- -15.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 178.21M | -34.7% |
| FY2024 | 2024-12-31 | 272.72M | -7.0% |
| FY2023 | 2023-12-31 | 293.14M | +7.5% |
| FY2022 | 2022-12-31 | 272.56M | -23.6% |
| FY2021 | 2021-12-31 | 356.91M | — |
Operating Expenses vs competitors
How SANA compares with its peers on the latest reported figures
- SANA's LTM Mar 2026 operating expenses of $235.17M is the 6th highest of the 11 companies compared; the peer median is $176.76M.
- Its year-over-year change of +10.6% is the 3rd highest of 11, against a peer median of -11.3%.
- Over three fiscal years its annual growth of -13.2% compares with a peer median of -4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $740.02M | -0.1% | +14.3% | 54.5% | |
| LTM Jun 2026 | $534.06M | +5.5% | +78.7% | 342.3% | |
| LTM Sep 2026 | $389.17M | +13.2% | -15.6% | 1546.0% | |
| LTM Mar 2026 | $319.11M | -10.9% | -0.7% | 482.8% | |
| LTM Mar 2026 | $240.35M | +15.1% | — | — | |
| LTM Mar 2026 | $235.17M | +10.6% | -13.2% | — | |
| LTM Mar 2026 | $113.16M | -11.7% | -28.7% | 1791.7% | |
| LTM Mar 2026 | $112.97M | -32.5% | -15.4% | — | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $82.81M | -13.0% | -1.4% | 183.7% | |
| LTM Mar 2026 | $28.55M | -83.6% | -4.9% | 123.4% | |
| Peer median (excluding SANA) | $176.76M | -11.3% | -4.9% | 342.3% | |
Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 12.75M |
| Gross Profit | 0 | 0 | 0 | 0 | (12.75M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 306.5M | 201M | 219.84M | 208.68M | 131.98M |
| Selling, General & Admin | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M |
| Operating Expenses | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M |
| Depreciation & Amortization | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M |
| EBITDA | (344.86M) | (253.85M) | (258.7M) | (249.37M) | (231.42M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (356.91M) | (272.56M) | (293.14M) | (272.72M) | (190.96M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 676K | 3.76M | 9.94M | 10.47M | 3.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 981K | 3.09M | 9.89M | 5.96M | (53.21M) |
| Income Before Tax | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (355.93M) | (269.48M) | (283.26M) | (266.76M) | (244.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| EPS (Diluted) | (2.14) | (1.43) | (1.46) | (1.16) | (0.96) |
| Weighted Avg Shares | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
| Weighted Avg Shares (Diluted) | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M |
Sana Biotechnology, Inc.
NASDAQ:SANA
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.